onctalk 2021 - pdl1 and imfinzi/durvalumab
Published 2 years ago • 88 plays • Length 7:45Download video MP4
Download video MP3
Similar videos
-
2:02
onctalk 2021 - immunotherapy in pdl1 and egfr
-
2:02
progression on pembrolizumab: patient without actionable mutations & low pd-l1 - lung cancer onctalk
-
2:13
lung cancer video library - immunotherapy in stage lll nsclc - the pacific trial and imfinzi
-
2:27
do you order pd-l1 testing before choosing an immune checkpoint inhibitor?
-
8:03
studies in anti-pd-l1 monotherapy for nsclc - lung cancer onctalk 2022
-
5:24
pdl1 as a biomarker for second line
-
6:38
asco 2021 lung recap: poseidon trial: durvalumab /- tremelimumab vs. chemo alone
-
5:06
case based panel discussion - egfr mutation and high pdl1 - what is the role of immunotherapy in tre
-
2:22
aegean trial: perioperative durvalumab for nsclc - onctalk lung 2023
-
3:29
are there clinically significant distinctions between pd-1 and pd-l1?
-
6:56
gracecast - leading treatment options for patients with negative tumor pd-l1 nsclc with dr. stephen
-
6:52
combination chemotherapy and immunotherapy for patients with high pd-l1 nsclc - 2022 program: lcvl
-
3:22
discussing biomarkers and pd-l1 testing with your doctor - lung cancer onctalk 2022
-
21:58
grace targeted therapies lung cancer 2021 - alk therapies-which one comes first, how do we sequence?
-
2:18
treatment of stage iv nsclc with high pd-l1 and atypical mutation - lung cancer onctalk 2022
-
7:01
case based panel discussion 2.6 alk positive and high pdl1 first line treatment for potentially comp
-
3:06
grace targeted therapies lung cancer 2021 - tki plus chemotherapy as a firstline treatment in ros1?
-
7:27
intro and cancer 101 - grace targeted therapies in lung cancer patient forum 2021
-
9:49
gracecast - treatment options for patients with nsclc and high tumor pd-l1 expression